Mersana Therapeutics Announces FDA Has Lifted Clinical Hold On Phase 1 Clinical Trial Of XMT-2056
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics (NASDAQ:MRSN) announced that the FDA has lifted the clinical hold on the Phase 1 clinical trial of XMT-2056, a systemically administered Immunosynthen STING-agonist ADC designed to target a novel human epidermal growth factor receptor 2 (HER2) epitope. The trial is investigating XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2. The FDA has granted orphan drug designation to XMT-2056 for the treatment of gastric cancer. In August 2022, Mersana entered into a global collaboration providing GSK plc with an exclusive option to co-develop and commercialize XMT-2056.
October 31, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The lifting of the FDA's clinical hold on Mersana's Phase 1 trial of XMT-2056 is positive news for the company. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
The lifting of the FDA's clinical hold allows Mersana to continue its Phase 1 trial of XMT-2056. This is a positive development for the company as it indicates progress in their drug development pipeline. This news could potentially increase investor confidence in the company's ability to bring new drugs to market, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100